The Personalized Psychological Treatment for Psychosis
Launched by POLISH ACADEMY OF SCIENCES · Sep 16, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "The Personalized Psychological Treatment for Psychosis," is looking at a new way to help people with psychosis, particularly those who experience delusions. The researchers want to see if a personalized version of a therapy called Metacognitive Training (MCT) works better than the standard MCT. In this trial, participants will be randomly assigned to receive either the classic MCT or the personalized MCT. The goal is to find out if those receiving the personalized treatment will show more improvement in their symptoms.
To join the trial, participants must be adults aged 18 to 65 who have been diagnosed with certain types of psychosis and have experienced specific symptoms in the past year. They should be stable and not expect any changes in their medication during the trial. However, people who have received MCT in the past year, have certain neurological conditions, or are at high risk for aggressive behavior or suicide will not be eligible. The trial is not yet recruiting participants, but it aims to provide new insights into effective treatments for psychosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Inpatients and outpatients with a DSM-IV-R and DSM-5 diagnosis of non-affective psychosis or Clinical High Risk for psychosis.
- • 2. Presence of positive symptoms during the last year (PANSS delusions, suspiciousness or grandiosity \>=3).
- • 3. Adults, 18 - 65 years of age
- • 4. Stable condition with no expected changes in medication (information from clinical services).
- • 5. Lack of severe cognitive deficits (global assessment or/and information from clinical services);
- Exclusion Criteria:
- • 1. Having received MCT in the previous year.
- • 2. Neurological disorder, a history of head trauma or premorbid IQ below 70 (based on medical reports and/or other sources);
- • 3. A score above 5 in the "Hostility" and the "Suspiciousness" items of the PANSS Positive subscale (to preserve group dynamics).
- • 4. aggressive behavior (reports from clinical services if available)
- • 5. High risk of suicide (verified with DIAMOND)
About Polish Academy Of Sciences
The Polish Academy of Sciences, a prestigious national research institution, is dedicated to advancing scientific knowledge and innovation in Poland and beyond. With a focus on interdisciplinary collaboration, the Academy supports a wide range of research initiatives, including clinical trials aimed at improving healthcare outcomes. Its commitment to rigorous scientific methodology and ethical standards ensures the integrity and reliability of its studies. By fostering partnerships with universities, healthcare providers, and industry stakeholders, the Polish Academy of Sciences plays a pivotal role in translating research findings into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Barcelona, , Spain
Valparaíso, , Chile
Strasbourg Cedex, , France
Warsaw, , Poland
Barcelona, Catalonia, Spain
Patients applied
Trial Officials
Łukasz Gawęda, Professor
Principal Investigator
The Institute of Psychology, Polish Academy of Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported